These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1466 related articles for article (PubMed ID: 18971320)

  • 41. Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.
    Shi Z; Jain S; Kim IW; Peng XX; Abraham I; Youssef DT; Fu LW; El Sayed K; Ambudkar SV; Chen ZS
    Cancer Sci; 2007 Sep; 98(9):1373-80. PubMed ID: 17640301
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
    Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
    Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
    Tang SC; Lankheet NA; Poller B; Wagenaar E; Beijnen JH; Schinkel AH
    J Pharmacol Exp Ther; 2012 Apr; 341(1):164-73. PubMed ID: 22238213
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.
    Matsson P; Pedersen JM; Norinder U; Bergström CA; Artursson P
    Pharm Res; 2009 Aug; 26(8):1816-31. PubMed ID: 19421845
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.
    Mathias TJ; Natarajan K; Shukla S; Doshi KA; Singh ZN; Ambudkar SV; Baer MR
    Invest New Drugs; 2015 Apr; 33(2):300-9. PubMed ID: 25597754
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models.
    Tiwari AK; Sodani K; Dai CL; Abuznait AH; Singh S; Xiao ZJ; Patel A; Talele TT; Fu L; Kaddoumi A; Gallo JM; Chen ZS
    Cancer Lett; 2013 Jan; 328(2):307-17. PubMed ID: 23063650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
    Robey RW; Shukla S; Finley EM; Oldham RK; Barnett D; Ambudkar SV; Fojo T; Bates SE
    Biochem Pharmacol; 2008 Mar; 75(6):1302-12. PubMed ID: 18234154
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A.
    Ejendal KF; Hrycyna CA
    Mol Pharmacol; 2005 Mar; 67(3):902-11. PubMed ID: 15598974
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Poller B; Wagenaar E; Tang SC; Schinkel AH
    Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.
    Shukla S; Sauna ZE; Ambudkar SV
    Leukemia; 2008 Feb; 22(2):445-7. PubMed ID: 17690695
    [No Abstract]   [Full Text] [Related]  

  • 52. Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.
    Strouse JJ; Ivnitski-Steele I; Waller A; Young SM; Perez D; Evangelisti AM; Ursu O; Bologa CG; Carter MB; Salas VM; Tegos G; Larson RS; Oprea TI; Edwards BS; Sklar LA
    Anal Biochem; 2013 Jun; 437(1):77-87. PubMed ID: 23470221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.
    Kuang YH; Patel JP; Sodani K; Wu CP; Liao LQ; Patel A; Tiwari AK; Dai CL; Chen X; Fu LW; Ambudkar SV; Korlipara VL; Chen ZS
    Biochem Pharmacol; 2012 Sep; 84(6):766-74. PubMed ID: 22750060
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.
    Strouse JJ; Ivnitski-Steele I; Khawaja HM; Perez D; Ricci J; Yao T; Weiner WS; Schroeder CE; Simpson DS; Maki BE; Li K; Golden JE; Foutz TD; Waller A; Evangelisti AM; Young SM; Chavez SE; Garcia MJ; Ursu O; Bologa CG; Carter MB; Salas VM; Gouveia K; Tegos GP; Oprea TI; Edwards BS; Aubé J; Larson RS; Sklar LA
    J Biomol Screen; 2013 Jan; 18(1):26-38. PubMed ID: 22923785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
    Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.
    Eadie LN; Hughes TP; White DL
    Clin Pharmacol Ther; 2014 Mar; 95(3):294-306. PubMed ID: 24107928
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib.
    Glodkowska-Mrowka E; Mrowka P; Basak GW; Niesiobedzka-Krezel J; Seferynska I; Wlodarski PK; Jakobisiak M; Stoklosa T
    Exp Hematol; 2014 Jun; 42(6):439-47. PubMed ID: 24667683
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2.
    Shukla S; Wu CP; Nandigama K; Ambudkar SV
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3279-86. PubMed ID: 18065489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters.
    Ivnitski-Steele I; Larson RS; Lovato DM; Khawaja HM; Winter SS; Oprea TI; Sklar LA; Edwards BS
    Assay Drug Dev Technol; 2008 Apr; 6(2):263-76. PubMed ID: 18205550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.
    Brendel C; Scharenberg C; Dohse M; Robey RW; Bates SE; Shukla S; Ambudkar SV; Wang Y; Wennemuth G; Burchert A; Boudriot U; Neubauer A
    Leukemia; 2007 Jun; 21(6):1267-75. PubMed ID: 17519960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 74.